Marina Biotech Describes Integrated Technology Platform for the Development of RNAi-, microRNA- and Antisense-based Therapeutics

Collaboration and Licensing Partners Fund Efforts in Local and Systemic Administration of Company’s Novel Delivery Systems; Marina Biotech Focuses on Clinical Pipeline and CRN Technology

BOTHELL, WA–(Marketwire – February 14, 2011) – Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today presented their integrated technology platform for the discovery of multiple oligonucleotide based therapeutics including RNAi-, microRNA- and antisense-based drugs at the BIO CEO and Investor Conference held today in New York City. J. Michael French, President and CEO of Marina Biotech, Inc. explained the strategy behind Marina Biotech’s acquisition of key intellectual property and technologies over the past year which has positioned it to provide multiple RNA-based therapeutic alternatives to pharma’s non-druggable target needs. With the Debiopharm partnership fully funding the development of the Company’s bladder cancer program using the Company’s proprietary DiLA2 delivery technology for local administration combined with licensee ProNAi funding a Phase 1 clinical trial using the Company’s proprietary Smarticles® delivery technology for systemic administration; the Company is focusing its financial resources on the Phase 1b/2a clinical trial of CEQ508 in Familial Adenomatous Polyposis (FAP) as well as development of its Conformationally Restricted Nucleotide technology (CRN) for the development of single-stranded oligonucleotide therapies.

(read the entire release… )

Subscribe to the miRNA blog

Thank you for subscribing.

Something went wrong.

Related Posts

Add Comment